India’s IPO market continues to remain active in 2026, with pharmaceutical and healthcare companies attracting growing investor interest. Rising healthcare awareness, increasing demand for injectable medicines, and expansion in generic pharmaceutical manufacturing are creating strong opportunities for companies operating in the pharma manufacturing segment.
Against this backdrop, Bio Medica Laboratories Limited is set to open its IPO on May 21, 2026. Here is a detailed insight into the company, its IPO, and the industry outlook.
About Bio Medica Laboratories Ltd.
Incorporated in August 2015, Bio Medica Laboratories Limited specialises in manufacturing pharmaceutical parenteral formulations. The company produces a wide range of ethical drugs, generic drugs, and over-the-counter medicines in liquid injectable and dry powder injectable forms.
These injectable products are available in:
- Single dose formats
- Multi dose formats
The company caters to both:
- Human healthcare
- Veterinary healthcare
Product Portfolio
- Liquid Injectables: 58 products
- Dry Powder Injectables: 15 products
Bio Medica Laboratories operates on a B2B contract manufacturing model, where formulations are developed according to client specific requirements and product specifications.
The company holds:
- Good Manufacturing Practices (GMP) certification
- Good Laboratory Practices (GLP) certification
Both certifications have been issued by the Food and Drugs Administration, Madhya Pradesh.
The company operates two manufacturing facilities located in Indore, Madhya Pradesh.
Competitive Strengths
- Multi product manufacturing capability
- Diversified injectable product portfolio
- Experienced promoters and management team
- Strong quality assurance systems
- Established client relationships
Bio Medica Laboratories IPO Details
Bio Medica Laboratories IPO is a book-building issue aggregating to ₹52.43 crore. The issue consists of a fresh issue and an offer for sale.
The company plans to utilise the proceeds towards loan repayment, expansion of manufacturing facilities, and general corporate purposes.
Important IPO Timeline
| Event | Date |
|---|---|
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Allotment Date (Tentative) | May 26, 2026 |
| Initiation of Refunds | May 27, 2026 |
| Credit of Shares to Demat | May 27, 2026 |
| Listing Date (Tentative) | May 29, 2026 |
Key IPO Details
| Particulars | Details |
|---|---|
| Face Value | ₹10 per share |
| Price Band | ₹132 to ₹139 per share |
| Lot Size | 1,000 Shares |
| Issue Type | Bookbuilding IPO |
| Total Issue Size | 37,72,000 shares (₹52 Cr) |
| Fresh Issue | 32,06,000 shares (₹45 Cr) |
| Offer for Sale | 3,77,000 shares (₹5 Cr) |
| Listing At | NSE SME |
| Market Cap (Pre IPO) | ₹174.79 Cr |
Issue Reservation
| Category | Shares Offered |
|---|---|
| QIB | 1.00% |
| NII (HNI) | 48.98% |
| Retail (RII) | 50.01% |
| Market Maker | 5.01% |
Lot Size of Bio Medica Laboratories IPO
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹2,78,000 |
| Retail (Max) | 2 | 2,000 | ₹2,78,000 |
| S-HNI (Min) | 3 | 3,000 | ₹4,17,000 |
| S-HNI (Max) | 7 | 7,000 | ₹9,73,000 |
| B-HNI (Min) | 8 | 8,000 | ₹11,12,000 |
Bio Medica Laboratories Ltd. Financials
The company has reported strong growth in revenue and profitability in recent years, supported by expansion in contract manufacturing operations and injectable product demand.
Key Company Financials (₹ Crore)
| Period Ended | Nov 30 2025 | Mar 31 2025 | Mar 31 2024 | Mar 31 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| Net Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Key Performance Indicators (KPI)
| KPI | Nov 30 2025 | Mar 31 2025 |
|---|---|---|
| ROE | 54.41% | 99.59% |
| ROCE | 23.22% | 48.20% |
| Debt to Equity | 2.23 | 1.02 |
| RoNW | 54.41% | 99.59% |
| PAT Margin | 30.35% | 25.64% |
| EBITDA Margin | 47.11% | 39.83% |
| Price to Book Value | — | 8.66 |
IPO Objects of the Issue
| Purpose | Amount (₹ Cr) |
|---|---|
| Repayment of loans | 6.50 |
| Setting up new manufacturing facility | 28.50 |
| General corporate purposes | Balance |
Bio Medica Laboratories Ltd.: Industry Outlook
- India’s injectable pharmaceutical market is witnessing strong growth due to increasing healthcare demand
- Rising adoption of generic medicines is supporting pharmaceutical manufacturing expansion
- Contract manufacturing in pharma is growing as companies focus on outsourcing production
- Demand for sterile injectable products is increasing across hospitals and healthcare institutions
- Government healthcare initiatives and export opportunities are expected to support long-term sector growth
Conclusion
Bio Medica Laboratories Limited operates in the pharmaceutical injectable manufacturing segment with a diversified product portfolio and established B2B contract manufacturing operations. The company has shown strong growth in profitability and manufacturing capabilities in recent years.
However, investors should carefully consider risks such as high debt levels, dependence on contract manufacturing clients, and intense competition in the pharmaceutical sector. Based on recent financial performance, the IPO appears aggressively priced and may be suitable for informed investors with a higher risk appetite and medium-term investment horizon.
